Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. - Wikidata - awgldk - TriplyDB

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

http://www.wikidata.org/entity/Q35584977

about

What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.Oromandibular dystonia: a serious side effect of capecitabine.Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients Role of Kampo medicine in integrative cancer therapy.ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Part 1: background, methodology, and clinical adoption of pharmacogenetics.Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.Pharmacogenetics of chemotherapy-induced nausea and vomiting.Pharmacogenomics and Implications for Nursing Practice.Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer.Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.Beneficial effects of naringenin in liver diseases: Molecular mechanisms.Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience Simulated Microgravity Altered the Metabolism of Loureirin B and the Expression of Major Cytochrome P450 in Liver of Rats

P2860

Q26798171-BE5700CF-B97B-42A9-AFCF-F4309BF47264 Q27022665-6777D904-D160-4660-83FE-4476B3579864 Q28547481-7FEB50D9-5871-4EB2-AE13-5CBDA9AD037E Q33888862-0B4EC4D5-0370-4BC5-98F8-FC39D05F606C Q35174812-4716331B-7E79-4C8E-8A52-360B5BE4707E Q36990461-2DABC701-71DC-4716-A02A-3C6CFB616E81 Q37044478-E891FC1A-9AF3-4B7A-86AA-A03AC8A4896F Q37652283-BB87A593-CE17-4A3D-8A1D-B2BAF9FBD58E Q37685527-F6BD7E54-DE3C-44FD-A6E0-C9FAFC3310BB Q37883726-3909FC70-B93D-4230-B651-42E6A09ED847 Q38050315-4EDCA5C9-F285-48E4-A50F-0B807D44409E Q38082728-FBBFD2A8-B910-49CA-9BE1-9BFB894E5674 Q38255726-15F33E0C-C74C-4F55-BB8A-14F260B861CF Q38330216-5676FE96-8285-4ED9-912D-A78A910E571C Q38607878-60BD8651-DC02-425D-B6DC-852ADE99B737 Q38834922-706C279A-40C9-4B63-B343-BD44D7F2D1A4 Q45916609-E50855D9-DF1D-4519-88E2-12FCD5F91D2D Q54113356-C3F13C1E-7E03-4008-B167-0AA6D408E300 Q57054536-C574B931-47E4-41B6-BF4F-6FC6CAA011A6 Q58122665-3E93C44F-0070-4C69-9FBD-8321EF84ADD3

P2860

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

http://www.wikidata.org/entity/Q35584977

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@ast

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@en

type

label

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@ast

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@en

prefLabel

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@ast

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@en

P1433

Q35584977-88087052-EAF3-4085-9CAA-AF42FFF18E88

P1476

Q35584977-2ED157D6-2D2A-410D-AD2E-F6302639CABC

P2093

Q35584977-644B9C91-A254-4EB6-9D7D-E6A2780D728C

Q35584977-7B164E28-4D25-4A31-997D-92FD3AC9693D

Q35584977-D36C3B22-502E-4C6D-AEE5-36C729791E7F

Q35584977-E4FABB29-765B-4FD1-902B-D56803653C68

P2860

Q35584977-00158362-80B4-41D9-961E-2BF33BED1D5E

Q35584977-00397186-FB84-4866-B2F0-FA73A45F48C9

Q35584977-029BF932-23E7-468E-93A3-77328BA3528D

Q35584977-02C7B6CD-CB13-4229-8C0A-A1280EEC8753

Q35584977-0671910F-C741-4563-9E2E-90FC1CD9785B

Q35584977-0A053BD6-F336-4DA2-B34C-9E3B4D48C759

Q35584977-0C4A6D02-1D33-4903-81AC-AFF27ED9E77B

Q35584977-116BECEE-AB2B-40FD-A3F7-69127CA9E6EF

Q35584977-11CC09F8-0553-41D0-867A-7D285F18DB12

Q35584977-13B14346-93A4-4E66-943F-C8818A8DDCF1

P304

Q35584977-3B6023C7-D9A8-429E-A3CA-DB38D1A3A91F

P31

Q35584977-1DB50ABA-9304-4DC0-833A-3860959BAE78

P356

Q35584977-844508BD-A5A1-410B-9A6C-6E03D97D0894

P433

Q35584977-E3C5B259-8CCE-479E-A67D-804EFA8E6C33

P478

Q35584977-53299361-5D54-487F-BB38-DF260B9B38B9

P577

Q35584977-5FCF929F-7CC4-4070-9672-5E1F64ADBBD4

P5875

Q35584977-B4599EDC-8936-47BF-A4FE-B43480C5400B

P698

Q35584977-61A21AF1-B309-443C-8360-03A6ABFDC351

P932

Q35584977-4D6F2169-13B2-4CB7-BF00-77C92142437E

P356

THEONCOLOGIST.2010-0259

P1433

P1476

Part 2: pharmacogenetic variab ...... I anticancer drug metabolism.

@en

P2093

Annemieke Cats

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Maarten J Deenen

http://www.w3.org/2001/XMLSchema#string

P2860

Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients

Essential binding and functional domains of human bleomycin hydrolase

A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.

P304

820-834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0259

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51183766

http://www.w3.org/2001/XMLSchema#string

P698

21632461

http://www.w3.org/2001/XMLSchema#string

P932

3228220

http://www.w3.org/2001/XMLSchema#string